Evidence map›Paper›PMID 34471499›Full record

ArticleComputational and structural biotechnology journal2021

A data-driven methodology towards evaluating the potential of drug repurposing hypotheses.

Lucía Prieto Santamaría, Esther Ugarte Carro, Marina Díaz Uzquiano, Ernestina Menasalvas Ruiz, Yuliana Pérez Gallardo, Alejandro Rodríguez-González

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and structural biotechnology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Applications of Artificial Intelligence in Drug Repurposing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  3. Review
  4. Protein sequence analysis in the context of drug repurposing.BMC medical informatics and decision making · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lucía Prieto SantamaríaCentro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28660 Boadilla del Monte, Madrid, Spain.
Esther Ugarte CarroCentro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28660 Boadilla del Monte, Madrid, Spain.
Marina Díaz UzquianoCentro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28660 Boadilla del Monte, Madrid, Spain.
Ernestina Menasalvas RuizCentro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28660 Boadilla del Monte, Madrid, Spain.
Yuliana Pérez GallardoEzeris Networks Global Services S.L., 28028 Madrid, Spain.
Alejandro Rodríguez-GonzálezCentro de Tecnología Biomédica, Universidad Politécnica de Madrid, 28660 Boadilla del Monte, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug repurposing has become a widely used strategy to accelerate the process of finding treatments. While classical

Indexed as

ACE, Angiotensin I Converting EnzymeAHR, Aryl Hydrocarbon ReceptorALK, Anaplastic Lymphoma KinaseAPI, Application Programming InterfaceCMap, Connectivity MapCOX-2, Cyclooxygenase 2CUI, Concept Unique IdentifierData integrationDisease understandingDISNET knowledge baseDRD3, Dopamine Receptor D3DR, Drug Repurposing or Drug RepositioningDrug-disease validationDrug repositioningDrug repurposingESR1, Estrogen Receptor 1ESR2, Estrogen Receptor 2FCGR2A, Fc Fragment Of IgG Receptor IIaFCGR3A, Fc Fragment Of IgG Receptor IIIaFCGR3B, Fc Fragment Of IgG Receptor IIIbGDA, Gene Disease AssociationICD-10-CM, International Classification of Diseases, 10th revision, Clinical ModificationID, IdentifierKDR, Kinase insert Domain ReceptorLTα, Lymphotoxin alphaMeSH-PA, Medical Subject Headings – Pharmacological ActionND, New DiseaseNLM, National Library of MedicineOD, Original DiseasePTGS2, Prostaglandin-endoperoxidase synthase 2SM, Supplementary MaterialSRD5A1, Steroid 5 Alpha-Reductase 1SRD5A2, Steroid 5 Alpha-Reductase 2TNFα, Tumour Necrosis Factor alphaUMLS, Unified Medical Language System

Identifiers

PMID34471499
PMCPMC8387760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.